Impact and safety of remote monitoring of heart failure patients managed with the HeartLogic algorithm: the HeartLogic France Cohort Study

Figures

• 

  Figure 1. Flow chart. Among the 310 patients included, one patient was excluded from the analysis because living in an area without coverage, preventing transmission of the HeartLogic index. Three other patients were included in the analysis but had no HeartLogic data available: two patients died, and one patient underwent device extraction before the first transmission.

• 

  Figure 2. HeartLogic alerts management. Among the 309 patients, 158 experienced a total of 406 alerts. These alerts resulted in no action for 55.9% of cases, medication adjustment alone in 36.9%, and hospitalization in 7.1%. n = number of alert cases. ACE, Angiotensin converting enzyme; ARB, Angiotensin II receptor blockers; ARNI, Angiotensin receptor-neprilysin inhibitor; MRA, Mineralocorticoid receptor antagonists.

• 

  Figure 3. Kaplan Meier curves for unscheduled hospitalizations for heart failure, all-cause death, cardiovascular death, heart failure death, unscheduled hospitalization for ventricular arrhythmia and atrial arrhythmia in the overall population. The cumulative incidences of first unplanned hospitalizations at 6 and 12 months were 4.2% [95% CI: 2.0–6.5] and 5.9% [95% CI: 3.3–8.6], respectively.

• 

  Figure 4. Analysis of unplanned hospitalizations for heart failure. Among the 24 unplanned hospitalizations for heart failure, 33.3% were not preceded by a HeartLogic alert. *One patient underwent a dosage adjustment of both diuretics and beta-blockers, while another patient had modifications to both diuretics and the sacubitril/valsartan therapy. ARNi, Angiotensin receptor-neprilysin inhibitor.